Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer.

Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C.

Nat Commun. 2018 Nov 7;9(1):4672. doi: 10.1038/s41467-018-07174-1.


RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.

Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M, Cuzick JM, Greenhalgh R, Boggis C, Motion J, Sergeant JC, Adams J, Evans DG.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):58-66. doi: 10.1158/1055-9965.EPI-17-0158. Epub 2017 Nov 2.


Benefits and challenges of incorporating citizen science into university education.

Mitchell N, Triska M, Liberatore A, Ashcroft L, Weatherill R, Longnecker N.

PLoS One. 2017 Nov 1;12(11):e0186285. doi: 10.1371/journal.pone.0186285. eCollection 2017.


Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team.

Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.


Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.

Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, Hasan J, Edmondson R, Winter-Roach B, Kitchener HC, Mould T, Hutson R, Hall G, Clamp AR, Perren T, Ledermann J, Jayson GC.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):760-765. doi: 10.1016/j.clon.2016.06.011. Epub 2016 Jul 9.


Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.

Haslett K, Franks K, Hanna GG, Harden S, Hatton M, Harrow S, McDonald F, Ashcroft L, Falk S, Groom N, Harris C, McCloskey P, Whitehurst P, Bayman N, Faivre-Finn C.

BMJ Open. 2016 Apr 15;6(4):e010457. doi: 10.1136/bmjopen-2015-010457. Erratum in: BMJ Open. 2016 Jul 18;6(7):e010457corr1.


Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.

Bayman N, Ardron D, Ashcroft L, Baldwin DR, Booton R, Darlison L, Edwards JG, Lang-Lazdunski L, Lester JF, Peake M, Rintoul RC, Snee M, Taylor P, Lunt C, Faivre-Finn C.

BMJ Open. 2016 Jan 27;6(1):e010589. doi: 10.1136/bmjopen-2015-010589.


Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer.

Bundred NJ, Stockton C, Keeley V, Riches K, Ashcroft L, Evans A, Skene A, Purushotham A, Bramley M, Hodgkiss T; Investigators of BEA/PLACE studies.

Breast Cancer Res Treat. 2015 May;151(1):121-9. doi: 10.1007/s10549-015-3357-8. Epub 2015 Apr 8.


Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.

Krebs MG, Renehan AG, Backen A, Gollins S, Chau I, Hasan J, Valle JW, Morris K, Beech J, Ashcroft L, Saunders MP, Dive C.

Clin Colorectal Cancer. 2015 Jun;14(2):115-22.e1-2. doi: 10.1016/j.clcc.2014.12.006. Epub 2014 Dec 31.


Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.

Thomson DJ, Ho KF, Ashcroft L, Denton K, Betts G, Mais KL, Garcez K, Yap BK, Lee LW, Sykes AJ, Rowbottom CG, Slevin NJ.

Acta Oncol. 2015 Jan;54(1):88-98. doi: 10.3109/0284186X.2014.958528. Epub 2014 Oct 3.


Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.

Quinn AM, Blackhall F, Wilson G, Danson S, Clamp A, Ashcroft L, Brierley J, Hasleton P.

Histopathology. 2012 Sep;61(3):454-64. doi: 10.1111/j.1365-2559.2012.04247.x. Epub 2012 Jun 11.


Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.

Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C.

Lung Cancer. 2012 Apr;76(1):72-7. doi: 10.1016/j.lungcan.2011.09.015. Epub 2011 Oct 19.


Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.

Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG.

Br J Cancer. 2011 Jun 28;105(1):22-7. doi: 10.1038/bjc.2011.202. Epub 2011 Jun 7.


Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.

Sheikh H, Colaco R, Lorigan P, Blackhall F, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C.

Lung Cancer. 2011 Oct;74(1):75-9. doi: 10.1016/j.lungcan.2011.01.020. Epub 2011 Feb 26.


Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.

Califano R, Griffiths R, Lorigan P, Ashcroft L, Taylor P, Burt P, Lee L, Chittalia A, Harris M, Faivre-Finn C, Thatcher N, Blackhall F.

Lung Cancer. 2011 Sep;73(3):338-44. doi: 10.1016/j.lungcan.2011.01.001. Epub 2011 Feb 5.


Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.

Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG.

Breast Cancer Res Treat. 2011 Jan;125(1):279-87. doi: 10.1007/s10549-010-1139-x. Epub 2010 Sep 1.


The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.

Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R, Danson S, Lorigan P, Thatcher N, Shepherd FA.

Ann Oncol. 2010 Oct;21(10):2023-8. doi: 10.1093/annonc/mdq067. Epub 2010 Mar 23.


The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, Lorigan P, Thatcher N, Blackhall FH, Shepherd FA.

Ann Oncol. 2010 Feb;21(2):232-7. doi: 10.1093/annonc/mdp300. Epub 2009 Aug 12.


Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.

Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A.

Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2318-24. doi: 10.1158/1055-9965.EPI-09-0171.


Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study.

Harvie MN, Bokhari S, Shenton A, Ashcroft L, Evans G, Swindell R, Howell A.

Fam Cancer. 2007;6(3):287-94. Epub 2007 Apr 12.


Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.

Booton R, Ward T, Heighway J, Ashcroft L, Morris J, Thatcher N.

J Thorac Oncol. 2006 Sep;1(7):679-83. Erratum in: J Thorac Oncol. 2007 Aug;2(8):734.. Booten, Richard [corrected to Booton, Richard].


Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.

Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G; Royal Marsden NHS Foundation Trust, Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R.

Clin Cancer Res. 2006 Dec 1;12(23):7033-8.


Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.

Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust, Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R.

Clin Cancer Res. 2006 Dec 1;12(23):7025-32.


Screening younger women with a family history of breast cancer--does early detection improve outcome?

Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, Boggis C, Wilson M, Duffy SW, Howell A.

Eur J Cancer. 2006 Jul;42(10):1385-90. Epub 2006 Jun 5.


Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.

Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, Morris J, Thatcher N.

Cancer. 2006 Jun 1;106(11):2421-7.


A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).

Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N.

Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7.


Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.

Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N.

J Natl Cancer Inst. 2005 May 4;97(9):666-74. Erratum in: J Natl Cancer Inst. 2005 Jun 15;97(12):941.


Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer.

Baka S, Ashcroft L, Anderson H, Lind M, Burt P, Stout R, Dowd I, Smith D, Lorigan P, Thatcher N.

J Clin Oncol. 2005 Apr 1;23(10):2136-44. Epub 2005 Feb 14.


Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.

Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N.

Cancer. 2003 Aug 1;98(3):542-53.


Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.

Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR.

J Clin Oncol. 2003 Jul 1;21(13):2551-7.


Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival.

Linforth R, Anderson N, Hoey R, Nolan T, Downey S, Brady G, Ashcroft L, Bundred N.

Clin Cancer Res. 2002 Oct;8(10):3172-7.


Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results.

Burgers JA, Arance A, Ashcroft L, Hodgetts J, Lomax L, Thatcher N.

Br J Cancer. 2002 Aug 27;87(5):562-6.


Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.

White SC, Anderson H, Jayson GC, Ashcroft L, Ranson M, Thatcher N.

Ann Oncol. 2000 Feb;11(2):201-6.


A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.

Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N.

Br J Cancer. 2000 Mar;82(6):1158-62.


A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

Jayson GC, Middleton M, Lee SM, Ashcroft L, Thatcher N.

Br J Cancer. 1998 Aug;78(3):366-9.


A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.

Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L.

Br J Cancer. 1993 Jun;67(6):1385-90.


A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.

Lind MJ, Gomm S, Simmonds AP, Ashcroft L, Kamthan A, Gurney H, Thatcher N.

Cancer Chemother Pharmacol. 1991;28(2):142-4.


Serum prolactin correlates with depressed mood during alcohol withdrawal.

Miller F, Barasch A, Sacks M, Levitan J, Ashcroft L.

Drug Alcohol Depend. 1986 Jul;17(4):331-8.


Antigenicity of T.A.B.C. vaccine after admixture with tetanus toxoid for various periods.

Hitch FG, Ashcroft LS, Green CA.

J Hyg (Lond). 1943 Sep;43(3):207-13. No abstract available.



Ashcroft LS, Cunningham L, McMurray TP, Pemberton HS.

Br Med J. 1925 Jul 4;2(3366):13. No abstract available.

Supplemental Content

Loading ...
Support Center